Epidemiology of invasive pneumococcal disease in the pre-conjugate vaccine era: South Africa, 2003-2008

Vaccine

Volumn 31, Issue 38, 2013, Pages 4200-4208

  von Gottberg, Anne ^a,b,c   Cohen, Cheryl ^a,d   de Gouveia, Linda ^a,b,c   Meiring, Susan ^a   Quan, Vanessa ^a   Whitelaw, Andrew ^e   Crowther Gibson, Penny ^a   Madhi, Shabir A ^a,c,f   Whitney, Cynthia G ^g   Klugman, Keith P ^a,b,c,h  

^a NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

^f UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^g NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^h EMORY UNIVERSITY   (United States)

Author keywords

Laboratory based surveillance; Pneumococcal disease; Pneumococcus; South Africa; Streptococcus pneumoniae; Vaccine preventable disease

Indexed keywords

PNEUMOCOCCUS VACCINE;

ARTICLE; BACTERIUM ISOLATE; CHILD; DISEASE SURVEILLANCE; FEMALE; HUMAN; INFANT; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTIPLE REGRESSION; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; SEROTYPE;

LABORATORY-BASED SURVEILLANCE; PNEUMOCOCCAL DISEASE; PNEUMOCOCCUS; SOUTH AFRICA; STREPTOCOCCUS PNEUMONIAE; VACCINE-PREVENTABLE DISEASE;

CHILD, PRESCHOOL; HIV INFECTIONS; HUMANS; INFANT; MULTIVARIATE ANALYSIS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SOUTH AFRICA; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 84881546341     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.04.077     Document Type: Article

References (39)

1. World Health Organization Pneumococcal vaccines WHO position paper - 2012 - recommendations. Vaccine 2012, May.
2. O'Brien K.L., Wolfson L.J., Watt J.P., Henkle E., Deloria-Knoll M., McCall N., et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009, 374(September (9693)):893-902.
3. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Lynfield R., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003, 348(May (18)):1737-1746.
4. Reingold A., Hadler J., Farley M.M., Harrison L., Lynfield R., Besser J., et al. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease - United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2005, 54(September (36)):893-897.
5. Pilishvili T., Lexau C., Farley M.M., Hadler J., Harrison L.H., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201(January (1)):32-41.
6. Kyaw M.H., Lynfield R., Schaffner W., Craig A.S., Hadler J., Reingold A., et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006, 354(April (14)):1455-1463.
7. Miller E., Andrews N.J., Waight P.A., Slack M.P., George R.C. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine 2011, 29(November (49)):9127-9131.
8. Cutts F.T., Zaman S.M., Enwere G., Jaffar S., Levine O.S., Okoko J.B., et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 2005, 365(March (9465)):1139-1146.
9. Klugman K.P., Madhi S.A., Huebner R.E., Kohberger R., Mbelle N., Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003, 349(October (14)):1341-1348.
10. Kemri-Wellcome Trust Research Programme. Research - epidemiology and demography: the Pneumoccocal Conjugate Vaccine Impact Study (PCVIS). Available at: [accessed 13.06.12]. http://www.kemri-wellcome.org/pcvis-current%20disease%20surveillance.
11. Huebner R.E., Klugman K.P., Matai U., Eggers R., Hussey G. Laboratory surveillance for Haemophilus influenzae type b, meningococcal, and pneumococcal disease. Haemophilus Surveillance Working Group. S Afr Med J 1999, 89(September (9)):924-925.
12. Centers for Disease Control and Prevention. Vaccines and immunizations: Publications - ACIP recommendations. Available at: [accessed 10.08.12]. http://www.cdc.gov/vaccines/pubs/acip-list.htm.
13. Statistics South Africa. StatsOnline: P0302 - Mid-year population estimates; 2010. Available at: [accessed 15.10.10]. http://www.statssa.gov.za/publications/P0302/P03022010.pdf.
14. du Plessis M., von Gottberg A., Madhi S.A., Hattingh O., de Gouveia L., Klugman K.P. Serotype 6C is associated with penicillin-susceptible meningeal infections in human immunodeficiency virus (HIV)-infected adults among invasive pneumococcal isolates previously identified as serotype 6A in South Africa. Int J Antimicrob Agents 2008, 32S(August):S66-S70.
15. Clinical and Laboratory Standards Institute (CLSI) (Formerly NCCLS) Performance standards for antimicrobial susceptibility testing; Eighteenth Informational Supplement. CLSI document M100-S18 ed. 2008, NCCLS, Wayne, Pennsylvania.
16. Dohoo I., Martin W., Stryhn H. Veterinary epidemiologic research 2003, Atlantic Veterinary College, Charlottetown, PE, Canada.
17. Berkley J.A., Lowe B.S., Mwangi I., Williams T., Bauni E., Mwarumba S., et al. Bacteremia among children admitted to a rural hospital in Kenya. N Engl J Med 2005, 352(January (1)):39-47.
18. O'Dempsey T.J., Mcardle T.F., Lloyd-Evans N., Baldeh I., Lawrence B.E., Secka O., et al. Pneumococcal disease among children in a rural area of west Africa. Pediatr Infect Dis J 1996, 15(May (5)):431-437.
19. Scott J.A. The preventable burden of pneumococcal disease in the developing world. Vaccine 2007, 25(March (13)):2398-2405.
20. Karstaedt A.S., Khoosal M., Crewe-Brown H.H. Pneumococcal bacteremia during a decade in children in Soweto, South Africa. Pediatr Infect Dis J 2000, 19(May (5)):454-457.
21. Nunes M.C., von Gottberg A., de Gouveia L., Cohen C., Moore D.P., Klugman K.P., et al. The impact of antiretroviral treatment on the burden of invasive pneumococcal disease in South African children: a time series analysis. AIDS 2011, 25(February (4)):453-462.
22. Klugman K.P., Madhi S.A., Adegbola R.A., Cutts F., Greenwood B., Hausdorff W.P. Timing of serotype 1 pneumococcal disease suggests the need for evaluation of a booster dose. Vaccine 2011, 29(April (18)):3372-3373.
23. Mhlanga B., Katsande R., Toscano C.M., Cherian T., O'Loughlin R., Rainey J., et al. Pediatric bacterial meningitis surveillance - African region, 2002-2008. MMWR Morb Mortal Wkly Rep 2009, 58(May (18)):493-497.
24. Whitney C.G., Pilishvili T., Farley M.M., Schaffner W., Craig A.S., Lynfield R., et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006, 368(October (9546)):1495-1502.
25. Hausdorff W.P., Bryant J., Kloek C., Paradiso P.R., Siber G.R. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. Clin Infect Dis 2000, 30(January (1)):122-140.
26. Hausdorff W.P., Siber G., Paradiso P.R. Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children. Lancet 2001, 357(March (9260)):950-952.
27. Crowther-Gibson P., Cohen C., Klugman K.P., de Gouveia L., von Gottberg A. Risk factors for multidrug-resistant invasive pneumococcal disease in South Africa, a setting with high HIV prevalence, in the prevaccine era from 2003 to 2008. Antimicrob Agents Chemother 2012, 56(October (10)):5088-5095.
28. Moore M.R., Whitney C.G. Emergence of nonvaccine serotypes following introduction of pneumococcal conjugate vaccine: cause and effect?. Clin Infect Dis 2008, 46(January (2)):183-185.
29. Moore M.R., Gertz R.E., Woodbury R.L., Barkocy-Gallagher G.A., Schaffner W., Lexau C., et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis 2008, 197(April 7):1016-1027.
30. Vesikari T., Wysocki J., Chevallier B., Karvonen A., Czajka H., Arsene J.P., et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 2009, 28(April (4 Suppl.)):S66-S76.
31. Crewe-Brown H.H., Karstaedt A.S., Saunders G.L., Khoosal M., Jones N., Wasas A., et al. Streptococcus pneumoniae blood culture isolates from patients with and without human immunodeficiency virus infection: alterations in penicillin susceptibilities and in serogroups or serotypes. Clin Infect Dis 1997, 25(November (5)):1165-1172.
32. Yu V.L., Chiou C.C., Feldman C., Ortqvist A., Rello J., Morris A.J., et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003, 37(July (2)):230-237.
33. Madhi S.A., Kuwanda L., Cutland C., Holm A., Kayhty H., Klugman K.P. Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children. Pediatr Infect Dis J 2005, 24(May (5)):410-416.
34. Madhi S.A., Kuwanda L., Cutland C., Klugman K.P. The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children. Clin Infect Dis 2005, 40(May (10)):1511-1518.
35. Zar H.J., Madhi S.A. Pneumococcal conjugate vaccine - a health priority. S Afr Med J 2008, 98(June (6)):463-467.
36. Nyasulu P., Cohen C., de Gouveia L., Feldman C., Klugman K.P., von Gottberg A. Increased risk of death in human immunodeficiency virus-infected children with pneumococcal meningitis in South Africa, 2003-2005. Pediatr Infect Dis J 2011, 30(December (12)):1075-1080.
37. Obaro S.K., Madhi S.A. Bacterial pneumonia vaccines and childhood pneumonia: are we winning, refining, or redefining?. Lancet Infect Dis 2006, 6(March (3)):150-161.
38. Feikin D.R., Klugman K.P. Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. Clin Infect Dis 2002, 35(September (5)):547-555.
39. Tyrrell G.J., Lovgren M., Ibrahim Q., Garg S., Chui L., Boone T.J., et al. Epidemic of invasive pneumococcal disease, western Canada, 2005-2009. Emerg Infect Dis 2012, 18(May (5)):733-740.